Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. - Wikidata - awgldk - TriplyDB

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

http://www.wikidata.org/entity/Q37629639

about

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.An overview of hereditary breast and ovarian cancer syndrome.A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges.Can mHealth Improve Risk Assessment in Underserved Populations? Acceptability of a Breast Health Questionnaire App in Ethnically Diverse, Older, Low-Income Women.Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system.Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients.Genetic risk and gynecologic cancers.Genetic testing in a gynaecological oncology care in developing countries-knowledge, attitudes and perception of Nepalese clinicians.Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.Use of BRCA Mutation Test in the U.S., 2004-2014.A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.A model for patient-direct screening and referral for familial cancer risk.A family history questionnaire improves detection of women at risk for hereditary gynecologic cancer: a pilot study.Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing.Ovarian Cancer Prevention in High-risk Women.Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.

P2860

Q26744525-CF076791-6354-482A-8A8A-D37A882BE5F7 Q26780387-5B99AED3-FB05-4567-B8F3-19D97BCDAB96 Q27009306-A02B44F1-E0C0-4E6B-B06F-6D8E86AFBDB1 Q33647706-93D58F0C-47DC-484D-B75A-968D222E72B6 Q33874719-F987FCE3-AAA1-46A2-867E-6FF37EAED126 Q34305000-DF796B51-FB49-4B08-9CAF-8418E3175F0B Q34856782-607F317B-2EBA-44E4-A0AD-0E2F36A77A91 Q35105485-02168D5C-482F-4D6E-9B13-240F4C3C5098 Q36108520-30B00506-96B1-4E34-8C2A-8AFAE6CDC3EA Q36130577-2ADDD5F4-8D14-482A-A7C4-602A3DD4DB2D Q36288206-FF2A6C87-DE51-418E-A73D-9FE38D72299D Q36706640-DD1B91CF-D48E-4479-9BF6-C1FDF09E20D9 Q36904144-FE9BCC0B-381A-4223-A9A2-07778690C4FF Q36925179-EFBD6F7E-4C84-42BF-9549-F8F9158FD616 Q37426280-C1D97877-F74A-46B6-8A0C-090597C5874F Q37468316-CCBECA74-6AAC-4CEE-AE9A-1EA1E3A0FFBF Q37472467-9D65B36E-75D9-4B62-89EF-3B715ACD0010 Q37492615-EB403C32-0D83-4941-B3CB-C5D04C2A8D97 Q37590728-8A6075F1-E66D-4E45-B1D5-2C28EE772698 Q37661436-DF34E149-503A-4F03-A20C-E520645F9909 Q37710168-A12EFEEE-D66D-4329-A066-45A8AC469D5F Q38371909-601EBF58-A043-4FE0-845D-5F7F6D455104 Q38727225-0A7C2F2E-596C-4F71-BEC0-6BB56B941AF2 Q38879087-A0FC59AD-BA2B-4D4D-97EC-2E1CA5FFF501 Q39230258-E62D8D20-B9AE-4A4F-9D2C-477A8D8868AF Q39992636-9FA31799-622A-4736-9E3C-CD1583C239F1 Q40445128-DE55C014-6147-4598-BCDD-2099417F2661 Q45068704-27ACCFF3-E41E-4AA4-82C6-E01A092E86BB Q46104940-2BD08B04-606B-4C9C-8E3F-13407B46E3B2 Q46109910-4C20416A-969B-47F2-A06C-7A91B5BEC9A4 Q47191699-21A7261B-9F90-45C1-BB19-A24D3B79C749 Q47397232-A1239DB3-7A1E-4DEF-ABD0-698A9D9A0745 Q48110433-981FC2D5-4A81-4520-8B7E-1D761BDEDEE8 Q48336651-0D5EABDB-2CEF-48DB-BB0F-749A2E2CC55C Q53140410-0450701A-C8DE-4769-84D1-E411E30AC5B3

P2860

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

http://www.wikidata.org/entity/Q37629639

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@en

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@nl

type

label

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@en

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@nl

prefLabel

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@en

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@nl

P1433

Q37629639-790511D4-36E7-4F10-9DF0-6799E4672065

P1476

Q37629639-7D0BD47C-07DD-4E16-AAB6-EE62F107B3F5

P2093

Q37629639-05025FFA-F0EA-449C-817D-E3D04A6C61D8

Q37629639-0C61A868-F30F-4585-9AF0-FAF82EF9F895

Q37629639-2B4B4B35-AEAE-4E00-8382-09BB8F9B91B6

Q37629639-7882CB06-160D-442E-98D6-BDE43A30C6B9

Q37629639-81F807CD-AE58-477B-BDE1-B5C7C920A407

Q37629639-B352C5E0-1B6C-4AA7-9A35-29DAD3F83FC6

Q37629639-BE23021C-C3E0-4395-9CA0-154A7C12379C

Q37629639-DCA431F6-8241-46E5-91DB-425EE3CC6FB8

Q37629639-FE11481F-B1F6-4D3F-94CE-FF8C1C58316C

P2860

Q37629639-0CE4AFA5-8481-4A35-9B85-0D504B2A3D3F

Q37629639-61AA3E52-AE31-4262-AB57-3E68730CAF97

Q37629639-652528A0-60D7-4A34-A11D-68E1E5118F64

Q37629639-848B55B3-49FF-4C84-BA93-9456315977FA

Q37629639-872EF53D-FD1D-49AC-A57D-576C54AE9F81

Q37629639-A858782A-A212-4E63-A404-F602214EFAEE

Q37629639-AD03A353-61B3-48B8-A4CF-D4D1B6E34A4D

Q37629639-B0B0DA75-E1CF-46C9-BADF-80C431C2CAAA

Q37629639-BF9E0715-08D8-4841-A0EB-67213BC32165

Q37629639-C95310D4-C614-4078-A881-CADBDC25A17C

P304

Q37629639-27572B0F-2E6A-41AF-B2EC-0D8C235F40D5

P31

Q37629639-CE19C255-AEB7-458D-94B5-30779F451DD1

P356

Q37629639-DF56EB46-05A0-452F-8348-6BC7131E4595

P407

Q37629639-5F4D7823-793B-4F1A-B194-BE91689D90AB

P433

Q37629639-379D5666-0F16-4C62-BD3D-5C4925ED29C7

P478

Q37629639-B1766D86-1B4C-4FB0-AC6F-2203CA230DE4

P50

Q37629639-D2B7BBA1-6E5B-4145-9498-095632BA09B4

P577

Q37629639-01FAFC57-5418-4094-9F40-C11EC32D37A4

P698

Q37629639-9218253E-24FC-4C27-8D4F-468E7F8F64A4

P921

Q37629639-E2454C9F-54D7-41F1-B9C4-6FFD3382E616

P932

Q37629639-88751409-7B26-44C1-8DDE-74079B1DC956

P356

AOG.0B013E3181DA08D7

P1433

Obstetrics and Gynecology

P1476

Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.

@en

P2093

Anuj Suri

http://www.w3.org/2001/XMLSchema#string

David M Gershenson

http://www.w3.org/2001/XMLSchema#string

Diana L Urbauer

http://www.w3.org/2001/XMLSchema#string

Graciela M Nogueras-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Karen H Lu

http://www.w3.org/2001/XMLSchema#string

Kathleen M Schmeler

http://www.w3.org/2001/XMLSchema#string

Larissa A Meyer

http://www.w3.org/2001/XMLSchema#string

Meaghan E Anderson

http://www.w3.org/2001/XMLSchema#string

Robin A Lacour

http://www.w3.org/2001/XMLSchema#string

P2860

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

Identification of the breast cancer susceptibility gene BRCA2

Factors influencing patients' decisions to decline cancer genetic counseling services.

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2

Improved survival in BRCA2 carriers with ovarian cancer

Who should be sent for genetic testing in hereditary colorectal cancer syndromes?

What women with ovarian cancer think and know about genetic testing

Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington.

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

P304

945-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/AOG.0B013E3181DA08D7

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Molly S. Daniels

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20410767

http://www.w3.org/2001/XMLSchema#string

P921

P932

5295824

http://www.w3.org/2001/XMLSchema#string